ID: ALA4521854

Max Phase: Preclinical

Molecular Formula: C19H14F3N5OS

Molecular Weight: 417.42

Molecule Type: Unknown

Representations

Canonical SMILES:  N#Cc1ccc(NC(=O)c2cc3n(n2)C(C(F)(F)F)CC(c2cccs2)N3)cc1

Standard InChI:  InChI=1S/C19H14F3N5OS/c20-19(21,22)16-8-13(15-2-1-7-29-15)25-17-9-14(26-27(16)17)18(28)24-12-5-3-11(10-23)4-6-12/h1-7,9,13,16,25H,8H2,(H,24,28)

Standard InChI Key:  FITXCLRWDSMQLY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 417.42

Molecular Weight (Monoisotopic): 417.0871

AlogP: 4.73

#Rotatable Bonds: 3

Polar Surface Area: 82.74

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 0.86

CX LogP: 3.90

CX LogD: 3.90

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.65

Np Likeness Score: -2.36

References

1. Madia VN, Messore A, Pescatori L, Saccoliti F, Tudino V, De Leo A, Scipione L, Fiore L, Rhoden E, Manetti F, Oberste MS, Di Santo R, Costi R..  (2019)  In Vitro Antiviral Activity of New Oxazoline Derivatives as Potent Poliovirus Inhibitors.,  62  (2): [PMID:30512950] [10.1021/acs.jmedchem.8b01482]

Source

Source(1):

• Scientific Literature